PrEP 2.0: TDF/FTC and Beyond – State of the Science and the Product and Delivery System Pipeline

Assessment of Needs

The IAS–USA offers this free state-of-the-art activity as part of a nationwide continuing medical education (CME) effort for physicians on the evolving challenges of managing HIV disease. We will review the current state of the evidence for daily and “on-demand” or “2-1-1” TDF-based PrEP, with a particular emphasis on differences in best practices based on route of HIV exposure.  In follow-up, we will also consider the near- and far-term pipelines for novel agents promising for use as PrEP, as well as novel delivery systems and timelines for anticipated evidence being available.  Finally, we will look at some challenges of making new/incident HIV diagnoses in the context of TDF-based PrEP.  The webinar will present Insights and approaches to troubleshooting difficult cases, and we will close with some forward-looking caveats about diagnosing new/incident infections in the context of the anticipated PrEP pipeline.

Learning Objectives

On completion of this webinar, learners will be able to:

• Describe the current evidence for the efficacy of TDF-based PrEP (daily and “on-demand”)
• Describe the range of PrEP agents currently in development
• Describe the challenges with HIV infection diagnosis in the PrEP context

Registration

Who Should Attend

This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.

This activity is also relevant for registered nurses, PharmDs, and other health professionals.

Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.

Registration closes on Monday, June 24, 2019, 4:00 PM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”

Faculty

Dr Landovitz has served as a consultant to Gilead Sciences, Inc, Merck & Co, Inc, and Roche. (Updated 06/25/19)

CME Planner and Reviewer

Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 06/25/19)